Chronic graft-vs-host disease (cGVHD) myositis is a rare complication of hematopoietic SCT, for which the pathogenesis and optimal therapy are unclear. We performed immunohistochemistry on muscle biopsies from pediatric cGVHD myositis and typical cases of autoimmune dermatomyositis and polymyositis. The immunostaining pattern of cGVHD myositis was distinct from that of typical cases of autoimmunity. There was a high proportion of CD20 þ and CD68 þ cells, and the best therapeutic response was achieved with rituximab (anti-CD20). These results suggest that cGVHD myositis may be mediated by different leukocytes than similar autoimmune diseases and that treatment may be optimized by targeting the specific cellular infiltrates identified in affected tissue.
Introduction
Chronic graft-vs-host disease (cGVHD) is a heterogeneous complication of hematopoietic SCT (HSCT) that rarely targets muscle. Although treatment of cGVHD is well studied, the optimal therapy for rare manifestations is unknown. cGVHD presenting with respiratory muscle weakness has only been reported in four publications. [1] [2] [3] Insight into the pathogenesis, course, prognosis and treatment of this disease is lacking, and rarity of this manifestation precludes clinical trials.
Although the pathogenesis of cGVHD is protean, recent data suggest a role for B cells. B-cell activating factors and autoantibodies have been associated with cGVHD, 4 and the blockade of developing B cells by rituximab, a MoAb against CD20, has ameliorated some manifestations of cGVHD in association with diminished alloantibodies.
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Given the increasing options for immunomodulatory therapy to treat cGVHD, there is a clinical need for tests that predict a patient's response to a particular therapy.
Here, we present a distinct immunohistochemical pattern in a case of cGVHD myositis presenting with respiratory weakness, compared with typical cases of autoimmune polymyositis and dermatomyositis. This cGVHD case presented with sudden hypercapneic respiratory failure and elevated serum creatinine kinase (CK), 4 years after unrelated donor HSCT and 2 months after withdrawal of immune suppression for cGVHD. The patient had an extensive work-up for respiratory decline, including bronchoalveolar lavage and viral serology negative for infection. EMG was normal. The diagnosis of cGVHD myositis was made by skeletal muscle biopsy showing endomysial inflammatory infiltrates, myofiber necrosis, myophagocytosis and minimal regeneration. This pretreatment muscle biopsy demonstrated B-cell infiltration, a pattern atypical for autoimmune myositis, and the best clinical response was achieved with rituximab (and CK levels normalized). Our results suggest that immunohistochemistry could be used to direct therapy in cGVHD, both in cases where standard therapies are ineffectual and potentially to guide initial treatment choices.
Materials and methods
Frozen muscle biopsy sections (7 mm) from the cGVHD (skeletal biopsy from extremity) and PM, DM and normal muscle control cases were labeled with antibodies to CD4 and CD8 (Invitrogen, Carlsbad, CA, USA), CD20 and CD68 (DAKO, Carpinteria, CA, USA), CD138 (Abcam, Cambridge, MA, USA) and MHC-I (Santa Cruz, Santa Cruz, CA, USA) after blocking with peroxidaseblocking solution (DAKO), revealed with horseradishperoxidase-labeled goat anti-mouse secondary Ab and 3,3-diaminobezidine chromagen (DAKO), and viewed with Nikon Optiphot-2 microscope. Immunostaining was rated qualitatively by two authors, controlled for degree of cellular infiltration. Representative digital images were captured with a Moticam 2500 digital camera.
Results and discussion
Our patient's pretreatment muscle biopsy demonstrated a preponderance of CD20 þ B cells compared with typical autoimmune polymyositis, and also robust staining for CD68 and MHC I (see Figure 1 and Table 1 ). Despite treatment with methylprednisolone 2 mg/kg/day, CYA, sirolimus and mycophenolate mofetil, the patient experienced 48 months of a relapsing remitting course characterized by severe weakness causing scoliosis, respiratory failure and dysphagia. Rituximab was then introduced and produced a rapid and durable clinical response, consistent with the observed muscle immunohistochemistry.
Only four prior cases of cGVHD presenting primarily with respiratory muscle weakness have been reported, [1] [2] [3] 6 one of which was diagnosed at autopsy. Thus, little is known about treatment of this rare complication of HSCT. A similar entity, GVHD PM, although rare (with an estimated incidence of 0.6% of cGVHD patients 7 ), has been better described. cGVHD PM is primarily considered a T-cell-mediated disease, with onset temporally linked both to donor lymphocyte infusion and to the onset of other cGVHD manifestations. 3, 6 Evidence for T-cell infiltration in cGVHD PM includes CD3 þ cells in the muscle, with some groups further characterizing these as donor CD8 þ cytotoxic T cells and one study identifying CD8 þ clonal T-cell populations with a specific Vb T-cell receptor family isolated from muscle. 8 These studies suggest that the pathology observed in cGVHD PM is similar to autoimmune PM, where T cells and macrophages have been shown to be major players. Consistent with these data, our cGVHD myositis and the PM and DM cases revealed comparable CD4 þ staining, and higher CD8 þ staining in both PM and cGVHD compared with DM ( Figure 1 , Table 1 ). CD20 þ B cells were also increased in the cGVHD case as compared with PM, and CD68 þ macrophages were markedly increased in our cGVHD case compared with the PM and DM cases (Table 1) .
Robust macrophage infiltration was evident in some regions of the biopsy (see Figure 1g) , where staining Figure 1 Immunohistochemistry of cGVHD, PM and DM biopsies for CD20 (a-c), CD4 (d-f) and CD68 (g-i). The proportion of CD20-positive cells in areas of inflammation was greater in the GVHD and DM cases (a, c). CD4 staining was comparable in all three cases. CD68, which stains macrophages, was extremely robust in areas of necrosis and inflammation in the GVHD case and also stained scattered cells throughout the biopsy (g), while only staining occasional cells in the other two cases (h, i). Qualitative rating of the degree of immunostaining was performed independently by two authors on a scale from +1 to +4. Representative fields are shown in Figure 1 . As the PM comparison case had less inflammatory infiltrate in general, the raters took into account the proportion of inflammatory cells staining for each marker.
for CD68 þ was more prominent than T-cell markers. The macrophage and B-cell staining might suggest a unique mechanism of disease, with CD68 þ macrophages and CD20 þ B cells acting as aberrant APCs, providing constant stimulation to infiltrating T cells, leading to destruction of myocytes. It is therefore not surprising that rituximab was the most effective treatment in this case, as it would directly deplete one arm of Ag presentation (CD20 þ B cells) and can occupy Fc binding sites on the other (CD68 þ macrophages). Interestingly, there are a few reported cases of myasthenia gravis-like presentations coincident with cGVHD myositis, further hinting at a role for alloantibodies and B-cell involvement. 9 We present the first immunohistochemical study of cGVHD myositis that links infiltration by CD 20 þ B cells with the pathogenesis of this rare manifestation of cGVHD. Rituximab has been reported for the treatment of rare cases of cGVHD myositis, with a positive response in 4/5 patients. 10, 11 Immunohistochemistry performed on cellular infiltrates has been suggested to justify therapy with rituximab in other autoimmune diseases, including Wegener's granulomatosis and multiple sclerosis. Therefore, we suggest that immunohistochemistry of target tissues in cGVHD can be used to tailor treatment regimens to possible disease mechanisms.
